How Much Does Evenity (Romosozumab) Cost in Arizona in 2026?

Arizona Retail Pricing for Evenity in 2026

The average cash-pay price for Evenity across Arizona retail pharmacies in 2026 is $1,825 per month, matching the national manufacturer list price set by Amgen and UCB. That figure reflects the cost of a single 210 mg dose administered as two separate 105 mg/1.17 mL prefilled syringes.

Because the FDA-approved course is 12 consecutive monthly injections, a patient paying entirely out of pocket faces a total outlay of approximately $21,900 1. Prices at individual pharmacies in Phoenix, Tucson, Flagstaff, and Mesa may vary by a small margin depending on the dispensing channel. Specialty pharmacies that ship statewide sometimes offer modest discounts compared to brick-and-mortar locations. Patients should request quotes from at least two pharmacies before committing to a dispensing location, since romosozumab is classified as a specialty drug and pricing is not always transparent at the counter.

The $1,825 figure also does not include administration costs. If a nurse or physician administers the injection in-office, expect an additional charge for the office visit and injection procedure, typically billed under CPT code 96372. Self-administration at home, when the prescriber permits it, eliminates that fee.

Why Romosozumab Commands a Premium Price

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein secreted by osteocytes that suppresses bone formation 2. No other approved osteoporosis drug targets this pathway. This mechanism is unique because it simultaneously stimulates bone formation and reduces bone resorption, a dual effect that separates it from both bisphosphonates and denosumab.

In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months 2. The FRAME trial (N=7,180) showed that romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months 3. These are among the largest fracture-risk reductions demonstrated by any single osteoporosis agent in phase III trials. The drug's biologic manufacturing process, limited competition in the sclerostin-inhibitor class, and time-limited 12-month treatment window all contribute to the high per-dose pricing. Amgen and UCB hold co-exclusive rights to romosozumab globally, and no biosimilar application has reached the FDA as of May 2026.

Arizona Medicaid Coverage: Currently Not Available

Arizona Health Care Cost Containment System (AHCCCS), the state's Medicaid program, does not cover Evenity for severe osteoporosis as of 2026. This applies across all AHCCCS managed care plans, including Mercy Care, Banner University Family Care, Arizona Complete Health, and UnitedHealthcare Community Plan.

Patients enrolled in AHCCCS who need anabolic osteoporosis therapy may still have options. Teriparatide (Forteo) and abaloparatide (Tymlos) are parathyroid hormone analogs that some AHCCCS plans do cover, typically after failure of or intolerance to bisphosphonates 4. However, neither of these drugs offers the same sclerostin-inhibiting mechanism. Patients and their prescribers can submit a prior authorization request citing clinical necessity, though approval for Evenity specifically under AHCCCS remains unlikely given the current formulary exclusion.

For dual-eligible patients (those enrolled in both Medicare and AHCCCS), Medicare Part B may cover Evenity if the drug is administered in a physician's office. The Medicare pathway bypasses the AHCCCS formulary entirely, but requires documentation of high fracture risk and, in many cases, evidence of prior bisphosphonate failure.

Commercial Insurance Coverage in Arizona

Most major commercial insurers operating in Arizona will cover Evenity with prior authorization. Blue Cross Blue Shield of Arizona, Cigna, Aetna, and UnitedHealthcare all include romosozumab on their specialty formularies, generally at a Tier 4 or Tier 5 level.

Prior authorization criteria typically require the prescriber to document three things: a confirmed diagnosis of osteoporosis (T-score of -2.5 or below at the spine or hip on DXA), high fracture risk per the FRAX calculator or a history of fragility fracture, and failure of or contraindication to at least one oral bisphosphonate. Some plans add a second step-therapy requirement, asking for documentation that denosumab was also tried or considered.

Once approved, the patient's out-of-pocket cost depends on their plan's benefit design. A specialty-tier copay can range from $100 to $500 per fill. High-deductible health plans may require the patient to cover the full $1,825 until the deductible is met. Patients should call the number on the back of their insurance card and ask for a benefits investigation specific to J-code J3111 (the HCPCS code for romosozumab injection) or, if dispensed through a specialty pharmacy, the pharmacy benefit NDC.

The Endocrine Society's 2020 clinical practice guideline recommends romosozumab as a first-line option for postmenopausal women at very high fracture risk, which can strengthen a prior authorization appeal if an initial request is denied 5.

The Amgen/UCB Savings Card: How It Works in Arizona

Amgen offers a co-pay savings program called the Evenity Access Card. Eligible commercially insured patients can reduce their per-dose copay to as little as $0 for up to 12 months of treatment. The maximum annual benefit is $12,000, meaning the card offsets up to $1,000 per monthly dose in copay or coinsurance charges.

Eligibility rules are straightforward. The patient must have commercial (private) insurance that covers Evenity. Patients enrolled in any government-funded program, including Medicare, Medicaid, TRICARE, or VA benefits, are not eligible for the savings card. Arizona residents with commercial coverage can enroll online through the Amgen patient support portal or by calling the number printed on the Evenity prescribing information.

The card works at the point of sale. When the specialty pharmacy processes the claim, the savings card acts as a secondary payer, covering the gap between the insurer's payment and the patient's copay obligation. If the patient's copay exceeds $1,000 in a given month, the patient pays only the difference. For most commercially insured Arizonans with specialty-tier copays in the $150 to $400 range, the card effectively reduces the out-of-pocket cost to zero.

There is one nuance worth noting. Copay accumulator programs, which some Arizona employers use, can prevent manufacturer copay cards from counting toward the patient's annual deductible or out-of-pocket maximum. If your employer's plan uses a copay accumulator, the savings card still reduces the immediate cost, but you may hit the same deductible burden again the following month. Ask your HR benefits coordinator whether your plan uses an accumulator or maximizer design.

Compounded Romosozumab in Arizona: Legal but Limited

Arizona permits 503A compounding pharmacies to prepare patient-specific formulations of romosozumab under a valid prescription. This is legal under both federal law (the Drug Quality and Security Act, Section 503A) and Arizona Revised Statutes Title 32, Chapter 18 governing pharmacy practice.

A critical distinction applies here. The fact that a 503A pharmacy can legally compound romosozumab does not mean the compounded product is equivalent to the branded Evenity product. Compounded biologics are not FDA-approved, do not undergo the same manufacturing controls as commercially produced monoclonal antibodies, and carry different risk profiles. The American Society of Health-System Pharmacists has raised concerns about the stability and potency of compounded monoclonal antibodies, and no published clinical trial has evaluated compounded romosozumab for fracture reduction.

Pricing for compounded romosozumab through Arizona 503A pharmacies is not standardized. Some pharmacies may offer it at a lower cost, but patients should discuss the clinical tradeoffs with their prescribing physician before pursuing this route. The FDA's position is that patients should use the commercially available product whenever it is accessible.

Medicare Part B Coverage for Arizona Residents

For Arizona residents aged 65 and older, or those under 65 with qualifying disabilities, Medicare Part B covers Evenity when it is administered in a physician's office or hospital outpatient setting. This falls under Medicare's "incident to" billing rules. The physician buys the drug, administers it, and bills Medicare using J-code J3111.

Under Part B, the patient is responsible for 20% coinsurance after meeting the annual Part B deductible ($257 in 2026). That means the patient's per-dose cost is roughly $365 (20% of $1,825) for each of the 12 injections, totaling about $4,380 out of pocket over the full course. A Medicare Supplement (Medigap) plan, if the patient carries one, may cover part or all of that 20% coinsurance.

Medicare Part D (the pharmacy benefit) does not typically cover Evenity, because romosozumab is classified as a physician-administered injectable. If a patient's Part D plan does list it, coverage would apply only when the drug is dispensed through a retail or specialty pharmacy for self-injection, which is less common.

Arizona Medicare Advantage plans (Part C) from carriers like Humana, UnitedHealthcare, and Banner Medicare Advantage may have different cost-sharing structures. Some charge a fixed specialty copay per injection rather than a percentage. Patients should verify the specific tier and copay with their Medicare Advantage plan before starting treatment.

Telehealth Prescribing of Evenity in Arizona

Arizona law permits the prescribing of Evenity via telehealth consultation. The Arizona Medical Board and the Arizona Board of Osteopathic Examiners both recognize telehealth as a valid modality for establishing a patient-provider relationship, which means a physician can evaluate your medical history, review DXA scan results, and issue a prescription for romosozumab without an in-person visit.

This is particularly relevant for patients in rural Arizona counties like Apache, Navajo, Greenlee, and La Paz, where access to endocrinologists or rheumatologists with osteoporosis expertise may require driving several hours. A telehealth consultation can connect patients with a specialist who then sends the prescription to a specialty pharmacy that ships statewide.

The prescription itself does not require an in-person visit, but the actual injection may. Some patients self-inject at home after training. Others receive injections at a local primary care office. Either arrangement works alongside a telehealth-initiated prescription.

Strategies to Lower Your Evenity Cost in Arizona

Several approaches can reduce the financial burden of a 12-month romosozumab course in Arizona.

Use the Amgen savings card first. If you have commercial insurance, this is the single most impactful cost-reduction tool. Enroll before your first dose.

Appeal a prior authorization denial. If your insurer denies coverage, ask your prescriber to submit a peer-to-peer review with the insurer's medical director. Include DXA results, FRAX scores, and documentation of prior bisphosphonate use or intolerance. Cite the Endocrine Society's 2020 guideline recommendation for very-high-risk patients 5.

Check specialty pharmacy pricing. Arizona has multiple specialty pharmacies that compete on romosozumab pricing. Accredo, CVS Specialty, and Optum Specialty are three of the largest. Request a price quote from each.

Explore patient assistance programs. Amgen's Safety Net Foundation provides free Evenity to patients who are uninsured or underinsured and meet income eligibility criteria (generally at or below 300% of the federal poverty level). Arizona residents can apply directly through Amgen's patient services line.

Ask about buy-and-bill versus pharmacy benefit. Some patients pay less when the drug is billed under their medical benefit (buy-and-bill at the physician's office) rather than the pharmacy benefit. The reverse is also sometimes true. Ask your prescriber's office to run a benefits check under both pathways.

Time your treatment around your deductible. If you have a high-deductible plan, starting your 12-dose course in January means you satisfy your deductible early in the calendar year and pay reduced cost-sharing for the remaining months.

Cardiovascular Safety: An Important Cost Consideration

The FDA-approved labeling for Evenity includes a boxed warning about potential cardiovascular risk 1. In the ARCH trial, a higher rate of major adverse cardiovascular events was observed in the romosozumab group compared with the alendronate group during the first 12 months (2.5% vs. 1.9%) 2. Evenity should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.

This matters for cost planning because some insurers use the boxed warning as grounds to impose stricter prior authorization criteria. Expect your insurer to require documentation that you have no history of recent cardiovascular events and possibly a cardiology clearance letter. Building this documentation into your prescriber's workflow before submitting the prior authorization can prevent delays and re-submissions.

"Romosozumab should be reserved for patients at very high fracture risk, particularly those with a recent osteoporotic fracture or a T-score of -3.0 or below, where the fracture-reduction benefit clearly outweighs the cardiovascular signal," according to the Endocrine Society's 2020 guideline on pharmacological management of osteoporosis in postmenopausal women 5.

The American Association of Clinical Endocrinology (AACE) 2020 guideline echoes this position: "In patients at very high fracture risk without recent cardiovascular events, romosozumab for 1 year followed by an antiresorptive is a recommended sequence" 6.

What Happens After the 12-Month Course

Romosozumab is approved for a maximum of 12 monthly doses. The bone-forming effect of sclerostin inhibition wanes after this period, and the FDA labeling does not support repeat courses. After completing Evenity, patients should transition to an antiresorptive agent, either a bisphosphonate like alendronate or zoledronic acid, or denosumab, to maintain the bone density gains achieved during the anabolic phase 2.

This sequencing matters financially. The follow-on therapy has its own costs. Generic alendronate is inexpensive (under $15/month). Zoledronic acid, given as a once-yearly IV infusion, runs approximately $1,200 per infusion at retail but is well covered by most insurers. Denosumab (Prolia) costs about $1,800 per twice-yearly injection at list price, though manufacturer savings programs exist for it as well. Planning the full treatment sequence, not just the romosozumab phase, gives patients a clearer picture of the total 2- to 3-year financial commitment.

Arizona patients completing their 12th Evenity dose should schedule a follow-up DXA scan within 1 to 3 months of the final injection to document the bone density response before transitioning to maintenance therapy.